DexCom is set to release its fourth-quarter earnings report, with analysts anticipating earnings per share of $0.6459 on revenues of $1.24 billion. Investors are closely monitoring the performance and market reception of the company's new G7 15-day continuous glucose monitoring (CGM) sensor rollout. This comes amidst increasing competitive pressures from Abbott Laboratories in the rapidly evolving CGM market. The success of the G7 launch is crucial for DexCom to maintain its market position and drive future growth. Furthermore, potential expansion of Medicare coverage for the G7 sensor could significantly bolster the company's outlook. These factors are vital for offsetting competitive headwinds and securing DexCom's long-term trajectory.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis